O'Neill James O, Starling Randall C, Khaykin Yaariv, McCarthy Patrick M, Young James B, Hail Melanie, Albert Nancy M, Smedira Nicholas, Chung Mina K
Department of Cardiovascular Medicine, Section of Heart Failure and Cardiac Transplant Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
J Thorac Cardiovasc Surg. 2005 Nov;130(5):1250-6. doi: 10.1016/j.jtcvs.2005.06.045.
Left ventricular reconstruction is performed in patients with ischemic cardiomyopathy and akinetic or dyskinetic left ventricular regions. These patients may remain at risk for malignant ventricular arrhythmias and hence may benefit from prophylactic implantable cardioverter-defibrillators. Specific guidelines for electrophysiologic testing and implantable cardioverter-defibrillator implantation in patients undergoing left ventricular reconstruction are lacking. We aimed to assess the residual risk and timing of ventricular arrhythmias after left ventricular reconstruction to determine whether electrophysiologic risk stratification or implantable cardioverter-defibrillator implantation can be safely deferred.
Data were prospectively gathered on 217 consecutive patients with left ventricular ejection fractions less than 40% undergoing left ventricular reconstruction at our institution from 1997 to 2002. Patients were divided into 3 groups: group 1, implantable cardioverter-defibrillator present before surgery; group 2, implantable cardioverter-defibrillator implanted early after surgery; and group 3, no implantable cardioverter-defibrillator implanted. End points were all-cause mortality (censored for cardiac transplantation) and appropriate implantable cardioverter-defibrillator therapies.
Of 217 patients (mean age, 61 +/- 10 years [mean +/- SD]), survival after a median follow-up of 381 days was 90%. Electrophysiologic studies successfully identified patients at low risk. Appropriate implantable cardioverter-defibrillator therapies occurred in 20% of group 1 and 12% of group 2. The median time to the first implantable cardioverter-defibrillator therapy from the time of left ventricular reconstruction was 43 days, and most first therapies (67%) occurred within the first 63 days.
The early event rates (occurring in the first 90 days after left ventricular reconstruction) support the use of predischarge electrophysiologic studies, implantation of implantable cardioverter-defibrillators before discharge from the hospital, or both.
对患有缺血性心肌病且左心室区域运动减弱或运动障碍的患者进行左心室重建。这些患者仍有发生恶性室性心律失常的风险,因此可能受益于预防性植入式心脏复律除颤器。目前缺乏针对接受左心室重建患者进行电生理检查和植入式心脏复律除颤器植入的具体指南。我们旨在评估左心室重建后室性心律失常的残余风险和发生时间,以确定是否可以安全推迟电生理风险分层或植入式心脏复律除颤器植入。
前瞻性收集了1997年至2002年在我们机构连续接受左心室重建的217例左心室射血分数低于40%的患者的数据。患者分为3组:第1组,术前已植入植入式心脏复律除颤器;第2组,术后早期植入植入式心脏复律除颤器;第3组,未植入植入式心脏复律除颤器。终点指标为全因死亡率(心脏移植 censored)和适当的植入式心脏复律除颤器治疗。
217例患者(平均年龄61±10岁[平均±标准差]),中位随访381天后生存率为90%。电生理检查成功识别出低风险患者。第1组20%和第2组12%发生了适当的植入式心脏复律除颤器治疗。从左心室重建到首次植入式心脏复律除颤器治疗的中位时间为43天,大多数首次治疗(67%)发生在最初63天内。
早期事件发生率(发生在左心室重建后的前90天内)支持出院前进行电生理检查、出院前植入植入式心脏复律除颤器或两者同时进行。